EcoDrugPlus


Trade Names	HIPREX METHENAMINE HIPPURATE UREX
Synonyms	Hexamine hippurate Hiprex Methenamine hippurate Urex
Status
Molecule Category	Mixture
UNII	M329791L57

Trade Names

HIPREX

METHENAMINE HIPPURATE

UREX

Synonyms

Hexamine hippurate

Hiprex

Methenamine hippurate

Urex

Status

Molecule Category

Mixture

UNII

M329791L57


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	ROAIXOJGRFKICW-UHFFFAOYSA-N
Smiles	C1N2CN3CN1CN(C2)C3.O=C(O)CNC(=O)c1ccccc1
InChI	InChI=1S/C9H9NO3.C6H12N4/c11-8(12)6-10-9(13)7-4-2-1-3-5-7;1-7-2-9-4-8(1)5-10(3-7)6-9/h1-5H,6H2,(H,10,13)(H,11,12);1-6H2

InChI Key

ROAIXOJGRFKICW-UHFFFAOYSA-N

Smiles

C1N2CN3CN1CN(C2)C3.O=C(O)CNC(=O)c1ccccc1

InChI

InChI=1S/C9H9NO3.C6H12N4/c11-8(12)6-10-9(13)7-4-2-1-3-5-7;1-7-2-9-4-8(1)5-10(3-7)6-9/h1-5H,6H2,(H,10,13)(H,11,12);1-6H2

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	PubMed PubMed DailyMed

Mechanism of Action

Action

Reference

DNA inhibitor

INHIBITOR

PubMed PubMed DailyMed

Resources	Reference
ChEBI	6825
ChEMBL	CHEMBL1201104
FDA SRS	M329791L57
KEGG	C01586
PubChem	21945
SureChEMBL	SCHEMBL3029
ZINC	ZINC00097685

Resources

Reference

ChEBI

ChEMBL

FDA SRS

KEGG

PubChem

SureChEMBL

ZINC


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

METHENAMINE HIPPURATE

Structure

Pharmacology

Cross References